ARTICLES BY NANCY BRADISH MYERS
-
![FDA headquarter iStock-1213293784]( "FDA User Fee Programs Reauthorized: FDA’s CBER Is A Clear Winner")
FDA User Fee Programs Reauthorized: FDA’s CBER Is A Clear Winner10/6/2022Last minute, squeaky clean! After years of planning, negotiation, and input, the user fee reauthorization bill was passed and signed into law on the very date that the programs were scheduled to sunset. This article sums up the key takeaways, CBER's reorganization with new product-specific offices, and more.
-
![donald-trump-1547274_640]( "Trump And The FDA: What to Expect (And What’s At Stake)")
Trump And The FDA: What to Expect (And What’s At Stake)11/22/2016Donald Trump’s advance team will soon be headed to FDA’s White Oak campus to observe and learn about the agency, to help facilitate the transition from the Obama administration to the Trump administration. In this article, I describe what I expect the nascent 2017 agenda will be as Trump’s team walks in the door, and I offer a few thoughts as to why the Trump team would do well to consider the unique nature of FDA as transition planning takes shape.
Nancy Bradish Myers
Nancy Bradish Myers, JD, president of Catalyst Healthcare Consulting, Inc., is a Washington, D.C.-based attorney with deep expertise in healthcare law and regulation, policy development, patient engagement, and government relations. She served as senior policy counsel in the Office of the FDA Commissioner, as well as special assistant/senior strategic advisor to the FDA acting deputy commissioner for operations. Myers has been closely involved in drug, biotechnology, and medtech regulatory issues for over 25 years. She currently advises clients on regulatory and health policy matters. You can reach her at nancy@catalysthcc.com or connect with her on LinkedIn.